**Question:** A patient having glaucoma develops blepharoconjunctivitis after instilling some anti-glaucoma drug. Which of the following drugs can be responsible for it:

A. Timolol
B. Latanoprost
C. Brimonidine
D. Timolol and Brimonidine

**Correct Answer:** D. Timolol and Brimonidine

**Core Concept:**

Blepharoconjunctivitis is an inflammation of the eyelids and conjunctiva, which can occur as an adverse reaction to certain medications. Anti-glaucoma drugs are a group of medications used to lower intraocular pressure in patients with glaucoma or ocular hypertension. The question is asking about two specific drugs that can potentially cause this adverse reaction in patients with glaucoma.

**Why the Correct Answer is Right:**

Timolol (Option A) and Brimonidine (Option C) are both beta-blockers and alpha-agonists, respectively, used to lower intraocular pressure in patients with glaucoma. Beta-blockers, such as Timolol, work by blocking beta-adrenergic receptors, which in turn reduces aqueous humor production and outflow. Brimonidine, being an alpha-agonist, increases outflow of aqueous humor through the uveoscleral pathway. However, both these drugs have been reported to cause ocular surface irritation, which can manifest as blepharoconjunctivitis in some patients.

**Why Each Wrong Option is Incorrect:**

Option B (Latanoprost) is a prostaglandin analogue that works by increasing the outflow of aqueous humor through the conventional pathway. Latanoprost is not known to cause blepharoconjunctivitis, hence it is the correct choice.

Option D (Timolol and Brimonidine) is the correct answer because these two drugs, when used together, can enhance the risk of ocular surface irritation and blepharoconjunctivitis due to their combined effects on the ocular surface. The combination of beta-blockers and alpha-agonists can lead to increased tear film evaporation and reduced tear film stability, which may result in blepharoconjunctivitis.

**Clinical Pearl:**

When treating glaucoma patients, it is essential to consider potential ocular surface irritation and inflammation caused by different drug combinations. In this case, the concurrent use of a beta-blocker and an alpha-agonist increases the risk of ocular surface irritation and blepharoconjunctivitis. This highlights the importance of careful choice of medications and monitoring for adverse effects when treating glaucoma patients. Always be mindful of potential drug interactions and their side effects.